STOCK TITAN

Biocryst Pharmaceuticals Inc reported $874.8M in revenue and $263.9M in net income for fiscal 2025. See the full BCRX financial statements: income statement, balance sheet, cash flow and ratios, each column linked to its SEC filing.

BioCryst to Present at Upcoming Investor Conference

BioCryst (Nasdaq:BCRX) will present at the Morgan Stanley 24th Annual Global Healthcare Conference in New York on Tuesday, September 15, 2026, at 9:15 a.m. ET.

(Neutral)
(Neutral)
Tags
conferences

BioCryst (Nasdaq:BCRX) will present at the Morgan Stanley 24th Annual Global Healthcare Conference in New York on Tuesday, September 15, 2026, at 9:15 a.m. ET. A live audio webcast and replay will be available via the Investors & Media section of the company’s website.

Loading...
Loading translation...

Positive

  • None.

Negative

  • None.

News Market Reaction – BCRX

+2.16%
1 alert
+2.16% Session close to close
$2.51B Market Cap
1.2x Rel. Volume

In the Sep 1 session, BCRX gained 2.16%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

RESEARCH TRIANGLE PARK, N.C., Sept. 01, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company plans to present at the Morgan Stanley 24th Annual Global Healthcare Conference in New York on Tuesday, September 15, 2026, at 9:15 a.m. ET.

The link to the live audio webcast and replay of the presentation may be accessed in the Investors & Media section of BioCryst’s website at www.biocryst.com.

About BioCryst Pharmaceuticals

BioCryst is a global biotechnology company focused on developing and commercializing medicines for hereditary angioedema (“HAE”) and other rare diseases, driven by its deep commitment to improving the lives of people living with these conditions. BioCryst has commercialized ORLADEYO® (berotralstat), the first oral, once-daily plasma kallikrein inhibitor and is advancing a pipeline of potential first-in-class or best-in-class therapeutics for rare diseases. For more information, please visit www.biocryst.com or follow us on LinkedIn.

BCRXW

Contact:

Investors:
investorrelations@biocryst.com

Media:
media@biocryst.com


FAQ

When will BioCryst (BCRX) present at the Morgan Stanley 24th Annual Global Healthcare Conference?

BioCryst will present on Tuesday, September 15, 2026, at 9:15 a.m. ET. According to BioCryst, the presentation is part of the Morgan Stanley 24th Annual Global Healthcare Conference held in New York.

How can investors listen to BioCryst's (BCRX) September 15, 2026 conference presentation?

Investors can listen via a live audio webcast available on BioCryst’s website. According to BioCryst, access is through the Investors & Media section, where a replay of the presentation will also be posted.

Where on BioCryst's website will the BCRX conference webcast and replay be available?

The webcast and replay will be available in the Investors & Media section of www.biocryst.com. According to BioCryst, both the live audio and replay can be accessed from this investor-focused area.

What event is BioCryst (BCRX) participating in on September 15, 2026?

BioCryst is participating in the Morgan Stanley 24th Annual Global Healthcare Conference in New York. According to BioCryst, the company plans to deliver a presentation with live audio webcast access for investors.

Will a replay of BioCryst's (BCRX) Morgan Stanley healthcare conference presentation be available?

Yes, a replay of the presentation will be available after the event. According to BioCryst, investors can access the replay via the Investors & Media section of the company’s official website, www.biocryst.com.